Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Esperion Therapeutics Inc (NASDAQ: ESPR) closed the day trading at $2.72 up 7.51% from the previous closing price of $2.53. In other words, the price has increased by $7.51 from its previous closing price. On the day, 7.2 million shares were traded. ESPR stock price reached its highest trading level at $2.745 during the session, while it also had its lowest trading level at $2.54.
Ratios:
For a better understanding of ESPR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.
BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 17 ’25 when Looker Benjamin sold 6,267 shares for $2.80 per share. The transaction valued at 17,573 led to the insider holds 393,670 shares of the business.
Koenig Sheldon L. sold 28,427 shares of ESPR for $79,254 on Sep 17 ’25. The President and CEO now owns 1,518,831 shares after completing the transaction at $2.79 per share. On Sep 17 ’25, another insider, Halladay Benjamin, who serves as the Chief Financial Officer of the company, sold 7,046 shares for $2.81 each. As a result, the insider received 19,785 and left with 474,862 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 630014080 and an Enterprise Value of 1060531072. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.19. Its current Enterprise Value per Revenue stands at 3.955 whereas that against EBITDA is -30.009.
Stock Price History:
The Beta on a monthly basis for ESPR is 0.91, which has changed by 0.2769953 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 13.08%, while the 200-Day Moving Average is calculated to be 63.24%.
Shares Statistics:
Over the past 3-months, ESPR traded about 6.71M shares per day on average, while over the past 10 days, ESPR traded about 10523210 shares per day. A total of 200.16M shares are outstanding, with a floating share count of 196.99M. Insiders hold about 2.30% of the company’s shares, while institutions hold 48.91% stake in the company. Shares short for ESPR as of 1759190400 were 27694381 with a Short Ratio of 4.13, compared to 1756425600 on 22348965. Therefore, it implies a Short% of Shares Outstanding of 27694381 and a Short% of Float of 13.8.
Earnings Estimates
Currently, 5.0 analysts are dedicated to thoroughly evaluating and rating the performance of Esperion Therapeutics Inc (ESPR) in the stock market.The consensus estimate for the next quarter is $0.24, with high estimates of $0.62 and low estimates of -$0.11.
Analysts are recommending an EPS of between $0.36 and -$0.48 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.04, with 6.0 analysts recommending between $0.35 and -$0.28.
Revenue Estimates
7 analysts predict $78.13M in revenue for. The current quarter. It ranges from a high estimate of $96.7M to a low estimate of $58.7M. As of. The current estimate, Esperion Therapeutics Inc’s year-ago sales were $51.63MFor the next quarter, 7 analysts are estimating revenue of $148.25M. There is a high estimate of $210.2M for the next quarter, whereas the lowest estimate is $65.3M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $439.4M, while the lowest revenue estimate was $236.52M, resulting in an average revenue estimate of $368.39M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $341.56M in the next fiscal year. The high estimate is $396.8M and the low estimate is $263.6M.
